ACT-20 in Patients With Severe COVID-19 Pneumonia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04398303|
Recruitment Status : Not yet recruiting
First Posted : May 21, 2020
Last Update Posted : May 21, 2020
|Condition or disease||Intervention/treatment||Phase|
|COVID-19 Pneumonia||Biological: ACT-20-MSC Biological: ACT-20-CM Biological: Placebo||Phase 1 Phase 2|
This study will assess the safety and efficacy of ACT-20-MSC and ACT-20-CM administered intravenously to subjects with moderate to severe COVID-19 related pneumonia in two parts.
Part 1 is an open-label study of 10 subjects, 5 with moderate COVID-19 pneumonia and 5 with severe COVID-19 pneumonia. Of these 10 subjects, 5 will receive ACT-20-CM and 5 will receive ACT-20-MSC resuspended in ACT-20-CM.
Part 2 is a randomized, blinded, placebo-controlled study of 60 patients, 30 with moderate COVID-19 pneumonia and 30 with severe COVID-19 pneumonia. Randomization will be 1:1:1 ACT-20-MSC in ACT-20-CM, ACT-20-CM or placebo. The placebo is MEM-α, a widely used sterile culture media that contains non-essential amino acids, nucleosides, vitamins, glucose, sodium pyruvate and lipoic acid.
Subjects treated at each investigative site will provide written informed consent prior to the conduct of any study-related procedures. Thereafter, they will be screened and those meeting the inclusion/exclusion criteria will be enrolled into the trial and undergo all the study procedures including the intravenous administration of the investigational medical product (IMP = ACT-20-MSC in ACT-20-CM or ACT-20-CM) or placebo. The IMP will be administered in addition to any standard of care treatment the subject is receiving.
Subjects will be assessed daily while in hospital. Following discharge from hospital, subjects will be following for an additional three month period.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||A Phase 1/2 Randomized, Placebo-Controlled Trial of ACT-20 in Patients With Severe COVID-19 Pneumonia|
|Estimated Study Start Date :||May 2020|
|Estimated Primary Completion Date :||October 2020|
|Estimated Study Completion Date :||October 2020|
Experimental: ACT-20-MSC in ACT-20-CM
Conventional treatment plus ACT-20-MSC in ACT-20-CM administered intravenously
1 million cells / kg body weight in 100 ml in conditioned media
Conventional treatment plus ACT-20-CM administered intravenously
100 ml of conditioned media only
Placebo Comparator: Placebo
Conventional treatment plus placebo (MEM-α) administered intravenously
100 ml of MEM-α
- Mortality at day 30 [ Time Frame: 30 days post treatment ]
- Ventilated Subjects - Ventilator Free Days [ Time Frame: 28 days post treatment ]Number of ventilator-free days
- Ventilated Subjects - Improvement in Ventilator Settings [ Time Frame: 28 days post treatment, or until off of ventilator ]Improvement in ventilator settings: Minute ventilation, PEEP, FiO2
- High-Flow O2 Support Subjects - Step-Down O2 Therapy [ Time Frame: 30 days post treatment, or until off of high-flow O2 support ]Days of step-down O2 therapy as evidenced by: improvement in required volume, change to nasal cannula or face mask delivery or improvement in required concentration.
- High Flow O2 Support Subjects - Respiration Rate [ Time Frame: 30 days post treatment, or until off of high-flow O2 support ]Respiration Rate < 30 for > 24 hours.
- Both Ventilated and High-Flow O2 Support Subjects - ICU-Free Days [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]Number of ICU-free days
- Both Ventilated and High-Flow O2 Support Subjects - Pulmonary Function Improvement [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]Improvement in pulmonary function as evidenced by A-A oxygen gradient, O2 saturation
- Both Ventilated and High-Flow O2 Support Subjects - Increased Berlin Score [ Time Frame: 30 days post treatment, or until off of ventilator or high-flow O2 support ]Increased Berlin Criteria score > 24 hours
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04398303
|Contact: Laura Fairbairnfirstname.lastname@example.org|